UK markets closed
  • NIKKEI 225

    30,526.88
    -711.06 (-2.28%)
     
  • HANG SENG

    17,195.84
    -135.38 (-0.78%)
     
  • CRUDE OIL

    84.44
    -4.79 (-5.37%)
     
  • GOLD FUTURES

    1,836.70
    -4.80 (-0.26%)
     
  • DOW

    33,129.55
    +127.17 (+0.39%)
     
  • Bitcoin GBP

    22,830.09
    +245.57 (+1.09%)
     
  • CMC Crypto 200

    589.12
    +4.96 (+0.85%)
     
  • NASDAQ Composite

    13,236.01
    +176.54 (+1.35%)
     
  • UK FTSE All Share

    4,010.91
    -32.81 (-0.81%)
     

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.